Biocryst Pharmaceuticals Incorporated (NASDAQ:BCRX) had an increase of 17.39% in short interest. BCRX’s SI was 12.04 million shares in April as released by FINRA. Its up 17.39% from 10.26 million shares previously. With 3.38M avg volume, 4 days are for Biocryst Pharmaceuticals Incorporated (NASDAQ:BCRX)’s short sellers to cover BCRX’s short positions. The SI to Biocryst Pharmaceuticals Incorporated’s float is 23.86%. About 652,316 shares traded. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has risen 104.88% since August 25, 2016 and is uptrending. It has outperformed by 96.12% the S&P500.
The stock of Gol Linhas Aereas Inteligentes SA (ADR) (NYSE:GOL) gapped up by $0.31 today and has $28.59 target or 4.00% above today’s $27.49 share price. The 8 months technical chart setup indicates low risk for the $575.81M company. The gap was reported on Apr, 3 by Barchart.com. If the $28.59 price target is reached, the company will be worth $23.03M more. About 94,131 shares traded. Gol Linhas Aereas Inteligentes SA (ADR) (NYSE:GOL) has risen 37.02% since August 25, 2016 and is uptrending. It has outperformed by 28.26% the S&P500.
Analysts await Gol Linhas Aereas Inteligentes SA (ADR) (NYSE:GOL) to report earnings on May, 10. They expect $0.15 earnings per share, down 44.44% or $0.12 from last year’s $0.27 per share. GOL’s profit will be $3.14M for 45.82 P/E if the $0.15 EPS becomes a reality. After $-0.26 actual earnings per share reported by Gol Linhas Aereas Inteligentes SA (ADR) for the previous quarter, Wall Street now forecasts -157.69% EPS growth.
Among 10 analysts covering Gol Linhas Aereas Inteligentes Sa (NYSE:GOL), 3 have Buy rating, 2 Sell and 5 Hold. Therefore 30% are positive. Gol Linhas Aereas Inteligentes Sa had 16 analyst reports since August 19, 2015 according to SRatingsIntel. Bank of America upgraded Gol Linhas Aereas Inteligentes SA (ADR) (NYSE:GOL) on Monday, January 30 to “Buy” rating. On Wednesday, September 9 the stock rating was downgraded by JP Morgan to “Underweight”. On Thursday, February 2 the stock rating was upgraded by Deutsche Bank to “Buy”. The firm earned “Hold” rating on Tuesday, January 5 by Deutsche Bank. The firm has “Neutral” rating given on Friday, August 5 by Bank of America. The firm earned “Underperform” rating on Thursday, December 10 by Credit Suisse. The stock has “Sell” rating by UBS on Tuesday, September 22. The firm has “Reduce” rating by HSBC given on Monday, November 23. The firm earned “Hold” rating on Wednesday, July 20 by Deutsche Bank. The stock of Gol Linhas Aereas Inteligentes SA (ADR) (NYSE:GOL) has “Neutral” rating given on Friday, August 26 by Credit Suisse.
Gol Linhas Aereas Inteligentes S.A. is an airline company. The company has market cap of $575.81 million. The Firm is engaged in providing mobile geolocation services to its passengers and designing a Website featuring accessibility resources to assist people with visual and motor impairments. It has a 3.5 P/E ratio. The Firm operates through two divisions: Air transportation and Loyalty program.
BioCryst Pharmaceuticals, Inc. is a biotechnology company. The company has market cap of $681.45 million. The Firm designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. It currently has negative earnings. The Firm focuses on the treatment of rare diseases.
Investors sentiment increased to 1.38 in Q4 2016. Its up 0.38, from 1 in 2016Q3. It is positive, as 14 investors sold BioCryst Pharmaceuticals, Inc. shares while 23 reduced holdings. 19 funds opened positions while 32 raised stakes. 52.04 million shares or 2.90% more from 50.57 million shares in 2016Q3 were reported. Northeast Financial Consultants Inc stated it has 20,000 shares. Millennium Mngmt Ltd has 186,994 shares for 0% of their portfolio. Panagora Asset Management Inc accumulated 31,477 shares or 0% of the stock. Blackrock Fund Advsr holds 0% or 3.40M shares. American International Gru owns 42,241 shares or 0% of their US portfolio. Da Davidson And reported 5,500 shares stake. Sg Americas Securities Limited Liability Company invested in 0% or 28,983 shares. Rhumbline Advisers has 0% invested in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Product Prtnrs holds 130,794 shares or 0.05% of its portfolio. Sei Investments Com holds 0% of its portfolio in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) for 442 shares. State Street Corporation has invested 0% in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Joel Isaacson & Communications Lc holds 9,000 shares. Glenmede Trust Communications Na accumulated 200 shares. D E Shaw & invested 0.04% in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Deerfield Mgmt holds 0.84% or 3.24M shares in its portfolio.
Since December 19, 2016, it had 0 insider buys, and 5 selling transactions for $163,996 activity. Shares for $25,675 were sold by STAAB THOMAS R II on Monday, March 6.
Among 9 analysts covering BioCryst Pharmaceuticals (NASDAQ:BCRX), 6 have Buy rating, 0 Sell and 3 Hold. Therefore 67% are positive. BioCryst Pharmaceuticals had 20 analyst reports since August 7, 2015 according to SRatingsIntel. Jefferies maintained it with “Hold” rating and $3 target in Friday, August 5 report. PiperJaffray upgraded the stock to “Overweight” rating in Friday, August 12 report. The stock has “Outperform” rating by FBR Capital on Tuesday, February 9. The rating was downgraded by Bank of America on Friday, October 9 to “Neutral”. The firm earned “Underperform” rating on Wednesday, November 11 by Bank of America. JMP Securities upgraded the stock to “Market Outperform” rating in Friday, December 16 report. Jefferies initiated BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) rating on Wednesday, September 9. Jefferies has “Hold” rating and $12 target. The stock of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) earned “Market Perform” rating by JMP Securities on Thursday, August 4. As per Friday, August 12, the company rating was upgraded by Piperjaffray. The rating was initiated by Ladenburg Thalmann on Thursday, February 16 with “Buy”.
